Weak pipeline? Why, Sanofi execs are suddenly over the moon about their prospects

It’s amazing what a vague top-line report on a Phase II study plus a relatively small bolt-on deal can do to a Big Pharma’s future prospects.

I’d say just ask new Sanofi CEO Paul Hudson, but you don’t have to. He’ll readily volunteer his growing enthusiasm now that he’s had a chance to settle into his leadership role. And you haven’t even been given a glimpse of what’s around the corner.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE

Weak pipeline? Why, Sanofi execs are suddenly over the moon about their prospects

This article is for premium subscribers only

Head of Regulated Labs Market Strategy

Benchling

San Francisco, CA, USA

Bristol Myers to shutter Bay Area cell therapy R&D facility as it eliminates jobs and costs

The next generation of AI biotechs is here. Can they deliver on the hype?

AbbVie beats first-quarter expectations, but Humira guidance leaves analysts confused

Sanders presses pharma leaders to change stance on Pandemic Accord proposals

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs

Updated: FDA approves Pfizer’s hemophilia B gene therapy, with $3.5M price tag

Weak pipeline? Why, Sanofi ex­ecs are sud­den­ly over the moon about their prospects

This article is for premium subscribers only

more like this

Head of Regulated Labs Market Strategy

Benchling

San Francisco, CA, USA

Bris­tol My­ers to shut­ter Bay Area cell ther­a­py R&D fa­cil­i­ty as it elim­i­nates jobs and costs

The next gen­er­a­tion of AI biotechs is here. Can they de­liv­er on the hype?

Ab­b­Vie beats first-quar­ter ex­pec­ta­tions, but Hu­mi­ra guid­ance leaves an­a­lysts con­fused

Sanders press­es phar­ma lead­ers to change stance on Pan­dem­ic Ac­cord pro­pos­als

UCB makes ma­jor man­age­ment changes; Bris­tol My­ers’ ADC part­ner tops list of new CEOs

Up­dat­ed: FDA ap­proves Pfiz­er’s he­mo­phil­ia B gene ther­a­py, with $3.5M price tag

Weak pipeline? Why, Sanofi execs are suddenly over the moon about their prospects

Bristol Myers to shutter Bay Area cell therapy R&D facility as it eliminates jobs and costs

The next generation of AI biotechs is here. Can they deliver on the hype?

AbbVie beats first-quarter expectations, but Humira guidance leaves analysts confused

Sanders presses pharma leaders to change stance on Pandemic Accord proposals

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs

Updated: FDA approves Pfizer’s hemophilia B gene therapy, with $3.5M price tag